As of November 6, 2026, Janux Therapeutics, Inc. is a publicly traded company (Nasdaq: JANX); its largest reported holder is Janus Henderson, with 6.9% on Schedule 13G/A of May 15, 2026, then BlackRock (6.7%). The largest insider holding is Avalon BioVentures SPV I, L.P., a 10% owner, with 7,377,765 shares (12.1% of shares outstanding), per Form 4 of October 18, 2024 (Schedule 13G/A, May 15, 2026).
Is this your company?
About to sign with, pay or invest in Janux Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Janux Therapeutics, Inc. a real, registered company?
- Janux Therapeutics, Inc. files with the SEC under CIK 1817713 (its SEC filings).
- Its shares are listed under the ticker JANX on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in San Diego, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Janux Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names BlackRock (filed 2026-07-28).
Who are Janux Therapeutics, Inc.'s owners and officers?
Janux Therapeutics, Inc.: incorporated in Delaware; business address in San Diego, California; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Point72 Asset Management, L.P. | 3.3% |
| Schedule 13G/A, 2026-08-13 | Janus Henderson Group LTD. | 0.3% |
| Schedule 13G/A, 2026-07-28 | Blackrock, Inc. | 6.7% |
| Schedule 13G/A, 2026-05-15 | Janus Henderson Group PLC | 6.9% |
| Schedule 13G, 2026-05-12 | State Street Corporation | 4.1% |
| Schedule 13G/A, 2026-05-06 | Fmr LLC | 4.2% |
| Schedule 13G, 2026-04-29 | Point72 Asset Management, L.P. | 5% |
| Schedule 13G, 2026-04-29 | Point72 Asset Management, L.P. | 5% |
| Schedule 13G/A, 2026-02-17 | Janus Henderson Group PLC | 8.9% |
| Schedule 13G, 2026-02-09 | State Street Corporation | 6.4% |
| Schedule 13G, 2026-02-06 | W. Lawrence Hawkins | 5.3% |
| Schedule 13G/A, 2026-01-08 | Fmr LLC | 5.8% |
Questions about who owns Janux Therapeutics, Inc.
Who owns Janux Therapeutics, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Janux Therapeutics, Inc.: Janus Henderson Group PLC (6.9%, Schedule 13G/A, filed 2026-05-15), Blackrock, Inc. (6.7%, Schedule 13G/A, filed 2026-07-28) and W. Lawrence Hawkins (5.3%, Schedule 13G, filed 2026-02-06).
Who are the largest shareholders of Janux Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Janux Therapeutics, Inc. on this page are Janus Henderson Group PLC (6.9%), Blackrock, Inc. (6.7%) and W. Lawrence Hawkins (5.3%).
When did Janus Henderson Group PLC buy into Janux Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Janus Henderson Group PLC on this page is the Schedule 13G/A, filed 2026-02-17, reporting 8.9%; its latest, Schedule 13G/A filed 2026-05-15, reports 6.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Janux Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Janux Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Janux Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Janux Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , L.P., a 10% owner: 7,377,765 shares (12.1% of shares outstanding), 2,071,799 held directly and 5,305,966 indirectly, on a joint filing (Form 4, 2024-10-18).
- , LP, a 10% owner: 7,377,765 shares (12.1% of shares outstanding), 2,071,799 held directly and 5,305,966 indirectly, on a joint filing (Form 4, 2024-10-18).
- Avalon Ventures XI, L.P., a 10% owner: 7,377,765 shares (12.1% of shares outstanding), 2,071,799 held directly and 5,305,966 indirectly, on a joint filing (Form 4, 2024-10-18).
- , a 10% owner: 6,560,816 shares (10.7% of shares outstanding), 7,000 held directly and 6,553,816 indirectly (Form 4, 2024-10-24).
- , the chief executive and president: 264,742 shares (0.43% of shares outstanding) (Form 4, 2026-07-31).
Shares outstanding: 61,183,417 as of 2026-11-03, from the company's latest SEC cover page.
How much has Janux Therapeutics, Inc. raised?
No fundraising or offering filing from Janux Therapeutics, Inc. is on file with us.
Keep reading
More on Janux Therapeutics, Inc. and the records around it.
Janux Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Prosight Management, LP also filed stake reports on 5 other companies: OnKure Therapeutics, Inc. (Aug 2026), ADC Therapeutics SA (Feb 2026), MeiraGTx Holdings plc (Feb 2026)
- Paradigm BioCapital Advisors LP also filed stake reports on 22 other companies: Obsidian Therapeutics, Inc. (Oct 2026), Spyre Therapeutics, Inc. (Oct 2026), Tyra Biosciences, Inc. (Sep 2026)
- Point72 Asset Management, L.P. also filed stake reports on 90 other companies: Immunocore Holdings plc (Nov 2026), Target Hospitality Corp. (Nov 2026), E.W. SCRIPPS Co (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/janux-therapeutics